Taselisib - CAS 1282512-48-4
Catalog number: 1282512-48-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activity against PI3K. This selectivity profile, and excellent pharmacokinetic and pharmaceutical properties, allowed for greater efficacy in vivo at the maximum tolerated dose relative to a pan Class I PI3K inhibitor in PIK3CA mutant xenografts. Notably, GDC-0032 preferentially inhibited PIK3CA mutant cells relative to cells with wild-type PI3K. GDC-0032 potently inhibits signal transduction downstream of PI3K and induces apoptosis at low concentrations in breast cancer cell lines and xenograft models that harbor PIK3CA mutations.
solid powder
GDC-0032; GDC0032; GDC 0032; RG7604; RG-7604; RG 7604; Taselisib.
Canonical SMILES:
Current Developer:
1.Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS1, Morse N2, Krigsfeld G3, Gupta G4, Higginson DS5, Lee NY5, Morris L2, Ganly I2, Shiao SL6, Powell SN5, Chung CH3, Scaltriti M2, Baselga J7. Clin Cancer Res. 2016 Apr 15;22(8):2009-19. doi: 10.1158/1078-0432.CCR-15-2245. Epub 2015 Nov 20.
PURPOSE: ActivatingPIK3CAgenomic alterations are frequent in head and neck squamous cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with radiation in HNSCC.
2.Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S1, Schwab CL2, Cocco E2, Bellone S2, Bonazzoli E2, English DP2, Schwartz PE2, Rutherford T2, Angioli R1, Santin AD3. Gynecol Oncol. 2014 Nov;135(2):312-7. doi: 10.1016/j.ygyno.2014.08.024. Epub 2014 Aug 27.
OBJECTIVE: To evaluate the efficacy of taselisib, a selective inhibitor of PIK3CA, against primary uterine serous carcinomas (USC) harboring PIK3CA mutations and HER2/neu gene amplification.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products

CAS 1276105-89-5 CNX-1351

(CAS: 1276105-89-5)

CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...

CAS 900515-16-4 AS-252424

(CAS: 900515-16-4)

AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.

CAS 154447-36-6 LY294002

(CAS: 154447-36-6)

LY294002 is a potent inhibitor of phosphoinositide PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively.

CAS 957209-68-6 NVP-QAV-572

(CAS: 957209-68-6)

NVP-QAV-572 is a potent PI3K kianse inhibitor.

CAS 371934-59-7 MDK34597

(CAS: 371934-59-7)

MDK34597 is a PI3K inhibitor.

CAS 371935-79-4 PI-103 Hydrochloride

PI-103 Hydrochloride
(CAS: 371935-79-4)

A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound

CAS 957054-30-7 GDC0941

(CAS: 957054-30-7)

GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.

(CAS: 1254036-71-9)

GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asth...

Chemical Structure

CAS 1282512-48-4 Taselisib

Quick Inquiry

Verification code

Featured Items